

PARTICULARS TO APPEAR ON THE OUTER PACKAGE - Box Label

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Nobilis Diluent Oculo Nasal

2. STATEMENT OF ACTIVE SUBSTANCES

Sterile phosphate buffered saline. Also contains EDTA and Patent Blue V

3. PACKAGE SIZE

10 x 31.5 ml

10 x 79.0 ml

4. TARGET SPECIES

Poultry.

5. INDICATIONS

Sterile diluent for reconstitution of Nobilis live vaccines authorised for oculonasal administration to poultry.

6. ROUTES OF ADMINISTRATION

Read instructions supplied with the vaccine carefully before use.

7. WITHDRAWAL PERIODS

Withdrawal period: Zero days.

8. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use immediately.

9. SPECIAL STORAGE PRECAUTIONS

Keep the container in the outer carton.

Do not store above 25 °C.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Intervet International BV

14. MARKETING AUTHORISATION NUMBERS

Vm 06376/4131

15. BATCH NUMBER

Lot {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE LABEL OF THE
DILUENT/SOLVENT (normal sized bottles)**

1. NAME OF THE DILUENT/SOLVENT

Nobilis Diluent Oculo Nasal

2. TARGET SPECIES

Poultry.

3. ROUTE(S) OF ADMINISTRATION

Read instructions supplied with the vaccine carefully before use.
Read the package leaflet before use.

4. EXPIRY DATE

Exp. {month/year}
Once broached use immediately.

5. SPECIAL STORAGE PRECAUTIONS

Keep the container in the outer carton.
Do not store above 25 °C.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Intervet International B.V.

7. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Nobilis Diluent Oculo Nasal

2. Composition

Diluent does not contain active ingredients.

Monobasic potassium phosphate

Disodium phosphate dihydrate

Sodium chloride

Disodium edetate

Patent Blue V (E131)

Water for injections

Clear, blue, solution.

3. Target species

Poultry.

4. Indications for use

Diluent for reconstitution of Nobilis live vaccine products authorised for oculonasal administration to poultry.

5. Contraindications

Any contraindications specified for the vaccine product for which the diluent is used for reconstitution will apply.

6. Special warnings

Special precautions for safe use in the target species:

No special precautions are required for handling the diluent however any recommendations specified for the vaccine product for which Nobilis Diluent Oculo Nasal is used as a diluent will apply.

Laying birds:

Any recommendations specified for the vaccine product for which Nobilis Diluent Oculo Nasal is used as the diluent will apply.

Overdose:

No specific treatment or antidote recommended.

7. Adverse events

Any adverse events specified for the vaccine product for which Nobilis Diluent Oculo Nasal is used as the diluent will apply.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

The instructions supplied with the vaccine product should be read carefully before using the diluent.

9. Advice on correct administration

For freeze dried vaccines the contents of the diluent vial should be transferred aseptically into the vial of freeze-dried vaccine immediately prior to use.

10. Withdrawal periods

Zero days.

11. Special storage precautions

Keep out of the sight and reach of children.

Do not store above 25 °C.

Keep the container in the outer carton.

Once broached use immediately.

In-use shelf life is that specified for the vaccine for which Nobilis Diluent Oculo Nasal is used as the diluent.

Do not use this veterinary medicinal product after expiry date which stated on the label after Exp.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 06376/4131

Pack sizes:

The product is supplied in cardboard boxes with 10 PET vials containing 31.5 or 79 ml closed with a halogenated butylrubber stopper and an aluminium crimp cap.

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and Manufacturer responsible for batch release:

Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Local representative:
MSD Animal Health UK Ltd.
Walton Manor, Walton
Milton Keynes, MK7 7AJ, United Kingdom

Contact details to report suspected adverse reactions:

UK(GB)
MSD Animal Health UK Ltd.
Tel.: +44 (0)1908 685685

UK(NI)
Intervet Ireland Ltd.
Tel.: +353 (0)1 2970220

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

POM-V

Gavin Hall
Approved: 05 March 2026